Aprea Therapeutics, Inc.
APREDrugs in Pipeline
5
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
How APRE's past catalysts played out
APR-246 + azacitidine
MDS
Pegylated Liposomal Doxorubicin Hydrochloride (PLD)
High-grade Serous Ovarian Cancer
APR-246
Acute Myeloid Leukemia or Myelodysplastic Syndromes
ATRN-119
Advanced Solid Tumor
Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD)
Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
APR-246 + azacitidine | Phase 3 | MDS | - | - |
Pegylated Liposomal Doxorubicin Hydrochloride (PLD) | Phase 2 | High-grade Serous Ovarian Cancer | - | - |
APR-246 | Phase 2 | Acute Myeloid Leukemia or Myelodysplastic Syndromes | - | - |
ATRN-119 | Phase 2 | Advanced Solid Tumor | - | - |
Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD) | Phase 2 | Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53 | - | - |
Frequently asked questions
What is in Aprea Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 5 drug candidates in Aprea Therapeutics, Inc.'s (APRE) pipeline across Phase 3, Phase 2. Its lead program is APR-246 + azacitidine (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Aprea Therapeutics, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Aprea Therapeutics, Inc. (APRE) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track APRE biotech catalysts?→
Add APRE to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Aprea Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.